{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:08Z","timestamp":1787026988573,"version":"build-2736575974"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Malignant ascites is the accumulation of fluid in the peritoneum as a result of advanced cancer and often signifies the terminal phase of the disease. Management of malignant ascites remains a clinical challenge as symptom palliation is the current standard of cure. Previously, studies examining malignant ascites largely focused on ovarian and gastric cancer. In recent years, there has been a significant increase in research on malignant ascites in pancreatic cancer. Malignant ascites is usually diagnosed based on positive cytology, but cytology is not always diagnostic, indicating the need for novel diagnostic tools and biomarkers. This review aims to summarize the current understanding of malignant ascites in pancreatic cancer and the recent advances in the molecular characterization of malignant ascites fluid from patients with pancreatic cancer including analysis of soluble molecules and extracellular vesicles. Current standard of care treatment options such as paracenteses and diuretics are outlined along with new emerging treatment strategies such as immunotherapy and small-molecule based therapies. New potential investigative directions resulting from these studies are also highlighted.<\/jats:p>","DOI":"10.3389\/fonc.2023.1138759","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T01:31:06Z","timestamp":1678930266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies"],"prefix":"10.3389","volume":"13","author":[{"given":"Margaret Y.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut H.","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","article-title":"The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data","volume":"10","author":"Bengtsson","year":"2020","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J Gastrointest Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199403000-00002","article-title":"Malignancy-related ascites and ascitic fluid \u201chumoral tests of malignancy\u201d","volume":"18","author":"Runyon","year":"1994","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0748-7983(96)80009-6","article-title":"Malignant ascites: a 2-year review from a teaching hospital","volume":"22","author":"Parsons","year":"1996","journal-title":"Eur J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.55167","article-title":"Management of ascites due to gastrointestinal malignancy","volume":"29","author":"Saif","year":"2009","journal-title":"Ann Saudi Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080521","article-title":"Ascitic fluid analysis in malignancy-related ascites","volume":"8","author":"Runyon","year":"1988","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J Am Coll Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198606000-00009","article-title":"Malignant ascites. clinical and experimental observations","volume":"203","author":"Garrison","year":"1986","journal-title":"Ann Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"B19","article-title":"The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma","volume":"32","author":"Feldman","year":"1972","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.seminoncol.2021.02.008","article-title":"Management problems in patients with pancreatic cancer from a surgeon\u2019s perspective","volume":"48","author":"Klose","year":"2021","journal-title":"Semin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12876-022-02487-4","article-title":"Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites","volume":"22","author":"Alshuwaykh","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000290","article-title":"Pancreatic cancer with malignant ascites: clinical features and outcomes","volume":"44","author":"Takahara","year":"2015","journal-title":"Pancreas"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.04.014","article-title":"Pancreas adenocarcinoma: Ascites, clinical manifestations, and management implications","volume":"15","author":"Hicks","year":"2016","journal-title":"Clin Colorectal Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1477-7819-4-16","article-title":"Prognostic significance of new onset ascites in patients with pancreatic cancer","volume":"4","author":"Zervos","year":"2006","journal-title":"World J Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2009.08.025","article-title":"Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA","volume":"71","author":"DeWitt","year":"2010","journal-title":"Gastrointest Endosc."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001262","article-title":"The significance of ascites in patients with pancreatic ductal adenocarcinoma: A case-control study","volume":"48","author":"Baretti","year":"2019","journal-title":"Pancreas"},{"key":"B27","article-title":"Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation","volume":"53","author":"Nagy","year":"1993","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.700","article-title":"Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i17.2468","article-title":"Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/jpm11121335","article-title":"Elevated interleukin-6 levels in the circulation and peritoneal fluid of patients with ovarian cancer as a potential diagnostic biomarker: A systematic review and meta-analysis","volume":"11","author":"Amer","year":"2021","journal-title":"J Pers Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15071","article-title":"Proteomic analysis of malignant ascites from patients with pancreatic ductal adenocarcinoma","volume":"41","author":"Kitamura","year":"2021","journal-title":"Anticancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201100264","article-title":"Mining the malignant ascites proteome for pancreatic cancer biomarkers","volume":"11","author":"Kosanam","year":"2011","journal-title":"Proteomics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712754","article-title":"Targeted sequencing of ascites and peritoneal washing fluid of patients with gastrointestinal cancers and their clinical applications and limitations","volume":"11","author":"Bae","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/109.6.704","article-title":"Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination","volume":"109","author":"Yamashita","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.3390\/ijms20133305","article-title":"C-met and PD-L1 on circulating exosomes as diagnostic and prognostic markers for pancreatic cancer","volume":"20","author":"Lux","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00795-019-00218-5","article-title":"Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer","volume":"52","author":"Sakaue","year":"2019","journal-title":"Med Mol Morphol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12953-014-0050-5","article-title":"New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions","volume":"12","author":"Klein-Scory","year":"2014","journal-title":"Proteome Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/clon.2002.0135","article-title":"The current and future management of malignant ascites","volume":"15","author":"Smith","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.09.008","article-title":"Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review","volume":"38","author":"Fleming","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_606_18","article-title":"Therapeutic results of Denver percutaneous peritoneovenous shunt in cancer patients with malignant ascites","volume":"16","author":"Tamagawa","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-016-0498-0","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy","volume":"7","author":"Valle","year":"2016","journal-title":"Indian J Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.05.030","article-title":"Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis","volume":"48","author":"Frassini","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq117","article-title":"Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study","volume":"40","author":"Shukuya","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.2017.009985","article-title":"Retrospective clinical study of advanced pancreatic cancer treated with chemotherapy and abdominal hyperthermia","volume":"4","author":"Fan","year":"2018","journal-title":"J Glob Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11792","article-title":"Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis","volume":"107","author":"Yamada","year":"2020","journal-title":"Br J Surg"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e8725","DOI":"10.1097\/MD.0000000000008725","article-title":"Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A\u00a0case report","volume":"96","author":"Liang","year":"2017","journal-title":"Med (Baltimore)."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.004","article-title":"Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108","volume":"63","author":"Jordan","year":"2016","journal-title":"Eur J Cancer."},{"key":"B51","article-title":"Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model","volume":"61","author":"Tomioka","year":"2001","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2021.01.045","article-title":"Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites","volume":"148","author":"Wang","year":"2021","journal-title":"Eur J Cancer."},{"key":"B53","article-title":"[A case of unresectable pancreatic cancer with massive cancerous ascites responsive to KM-CART]","volume":"48","author":"Shirakawa","year":"2021","journal-title":"Gan to Kagaku Ryoho."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.22-00150","article-title":"[IFN-gamma and IL-12 from concentrated ascites in patients with pancreatic cancer exerts growth inhibitory effects against pancreatic cancer cells]","volume":"142","author":"Kobori","year":"2022","journal-title":"Yakugaku Zasshi."},{"key":"B55","article-title":"Autologous ex vivo expanded NK cells combined with PD-1 inhibitor improved ascitic fluid immune microenvironment of peritoneal metastatic pancreatic cancer: a case study","volume":"15","author":"Chen","year":"2023","journal-title":"Am J Transl Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1608705","article-title":"Symptomatic fluid drainage: Peritoneovenous shunt placement","volume":"34","author":"Yarmohammadi","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1237","article-title":"The fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells","volume":"83","author":"Zeidler","year":"2000","journal-title":"Br J Cancer."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1125-8","article-title":"Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00538-y","article-title":"Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer","volume":"52","author":"Eum","year":"2020","journal-title":"Exp Mol Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"BSR20212093","DOI":"10.1042\/BSR20212093","article-title":"Capturing tumour heterogeneity in pre- and post-chemotherapy colorectal cancer ascites-derived cells using single-cell RNA-sequencing","volume":"41","author":"Poonpanichakul","year":"2021","journal-title":"Biosci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-023-36310-9","article-title":"Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1138759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T01:31:10Z","timestamp":1678930270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1138759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":63,"alternative-id":["10.3389\/fonc.2023.1138759"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1138759","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1138759"}}